Overview

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

Phase:

Phase 2

Details

Lead Sponsor:

The University of Texas Health Science Center at San Antonio

Collaborator:

Imago BioSciences,Inc.